Acute kidney injury associated with smoking synthetic cannabinoid

Clinical Toxicology

Volumn 52, Issue 7, 2014, Pages 664-673

  Buser, G L ^a,b   Gerona, R R ^c   Horowitz, B Z ^d   Vian, K P ^e   Troxell, M L ^f   Hendrickson, R G ^d   Houghton, D C ^f   Rozansky, D ^d   Su, S W ^g   Leman, R F ^a  

^a OREGON HEALTH AUTHORITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Communicable Disease and Immunization Programs Douglas County Public Health ^*  (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Randall Children's Hospital at Legacy Emanuel   (United States)

Author keywords

Electronspray ionization; Epidemiology; Mass; Public health; Spectrometry; Substance related disorders

Indexed keywords

CANNABINOID; CREATININE; ILLICIT DRUG; SYNTHETIC CANNABINOID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTICLE; CANNABIS SMOKING; DIALYSIS; HUMAN; HUMAN TISSUE; MALE;

ELECTRONSPRAY IONIZATION; EPIDEMIOLOGY; MASS; PUBLIC HEALTH; SPECTROMETRY; SUBSTANCE-RELATED DISORDERS;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; CANNABINOIDS; DESIGNER DRUGS; DRUG COMBINATIONS; HUMANS; KIDNEY; MALE; OREGON; POISON CONTROL CENTERS; POISONING; PSYCHOTROPIC DRUGS; SMOKE; STREET DRUGS; TREATMENT OUTCOME; WASHINGTON; YOUNG ADULT;

EID: 84905497636     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2014.932365     Document Type: Article

References (61)

1. Huffman JW, Padgett LW. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 2005 ; 12 : 1395-1411.
2. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006; 30: S13-S18.
3. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012 ; 1248 : 18-38.
4. U.S. DEA. 2011. National Forensic Laboratory DEA. Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010. Springfield, VA: U.S. Drug Enforcement Administration.
5. European Monitoring Centre for Drugs and Drug Addiction 2 009 Thematic paper - Understanding the Spice phenomenon. Luxembourg: Office for Official Publications of the European Communities, 37 pp.
6. Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. CMAJ 2008 ; 178 : 1685-1686.
7. Castellanos D, Singh S, Thornton G, Avila M, Moreno A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011 ; 49 : 347-349.
8. Meyer MR, Peters FT. Analytical toxicology of emerging drugs of abuse-an update. Ther Drug Monit 2012 ; 34 : 615-621.
9. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013 ; 44 : 360-366.
10. Lapoint J, James L P, Moran C L, Nelson L S, Hoffman R S, M oran J H. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011 ; 49 : 760-764.
11. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013 ; 108 : 534-544.
12. Alhadi S, Tiwari A, Vohra R, Gerona R, Acharya J, Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013 ; 9 : 199-206.
13. Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012 ; 8 : 62-64.
14. SAMSHA. 2011. Drug Abuse Warning Network (DAWN) 2010 ER Drug-related Visits.Substance Abuse and Mental Health Services Administration.
15. American Association of Poison Control Centers. Synthetic Marijuana Data: March 31, 2013. Available from: http://www.aapcc.org/alerts/synthetic- marijuana/. Accessed 26 June 2013.
16. National Conference of State Legislatures. Synthetic Cannabinoids (a.k.a. "K2 " /" Spice " ) Enactments. Available from: http://www.ncsl. org/issues-research/justice/synthetic-cannabinoids-enactments. aspx. Accessed 26 June 2013.
17. Thornton SL, Lo J, Clark RF, Wu AH, Gerona RR. Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis. Clin Toxicol (Phila) 2012 ; 50 : 1165-1168.
18. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012 ; 50 : 733-742.
19. Gerona RR, Wu AH. Bath salts. Clin Lab Med 2012 ; 32 : 415-427.
20. Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012 ; 36 : 360-371.
21. Ammann J, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 1 - Synthetic cannabinoids. J Anal Toxicol 2012 ; 36 : 372-380.
22. Yanes EG, Lovett DP. High-throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using saltingout sample preparation and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2012 ; 909 : 42-50.
23. Grabenauer M, Krol WL, Wiley JL, Thomas BF. Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. Anal Chem 2012 ; 84 : 5574-5581.
24. Di Paolo N, Guarnieri A, Loi F, Sacchi G, Mangiarotti AM, Di Paolo M. Acute renal failure from inhalation of mycotoxins. Nephron 1993 ; 64 : 621-625.
25. Warden CR, Benjamin DR. Acute renal failure associated with suspected Amanita smithiana mushroom ingestions: a case series. Acad Emerg Med 1998 ; 5 : 808-812.
26. Oubrahim H, Richard JM, Cantin-Esnault D. Peroxidase-mediated oxidation, a possible pathway for activation of the fungal nephrotoxin orellanine and related compounds. ESR and spin-trapping studies. Free Radic Res 1998 ; 28 : 497-505.
27. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004; 114: 555-576.
28. Galli J A, Sawaya R A, Friedenberg F K. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011 ; 4 : 241-249.
29. Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics 2012 ; 53 : 212-219.
30. Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA. Emergence and properties of spice and bath salts: a medicinal chemistry perspective. Life Sci 2014 ; 97 : 9-19.
31. Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci 2014 ; 97 : 55-63.
32. Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62 : 93-98.
33. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 2013 ; 8 : 523-526.
34. Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila) 2013 ; 51 : 189-190.
35. Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. Mil Med 2012 ; 177 : 1041-1048.
36. Johnston LD, O Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 2012 overview, key findings on adolescent drug use. University of Michigan, Institute for Social Research, 2013.
37. U.S. Renal Data System. USRDS 2012 Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012. pp 97-108.
38. Coca S G, Singanamala S, P arikh C R. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012 ; 81 : 442-448.
39. Mammen C, Al Abbas A, Skippen P, Nadel H, Levine D, Collet JP, Matsell DG. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012 ; 59 : 523-530.
40. Lopes J A, Fernandes P , Jorge S , Goncalves S , Alvarez A , Costa e Silva Z , et al . Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the Acute Kidney Injury Network classifi cations . Crit Care 2008 ; 12 : R110 .
41. Langer N, Lindigkeit R, Schiebel HM, Ernst L, Beuerle T. Identification and quantification of synthetic cannabinoids in spice-like herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal. 2013.
42. Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 2006 ; 21 : 2577-2582.
43. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther 2013 ; 17 : 165-184.
44. Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, et al. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem. 2013 ; 85 : 9390-9399.
45. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012 ; 40 : 2174-2184.
46. Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 2011 ; 39 : 1967-1976.
47. Kneisel S, Teske J, Auwarter V. Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. Drug Test Anal 2014 ; 6 : 135-136.
48. Teske J, Weller JP, Fieguth A, Rothamel T, Schulz Y, Troger HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010 ; 878 : 2659-2663.
49. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity? Life Sci 2014 ; 97 : 45-54.
50. U.S. DEA, 2011. National Forensic Laboratory DEA. Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010. Springfield, VA: U.S. Drug Enforcement Administration.
51. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 2012.
52. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation . Br J Pharmacol 2008 ; 153 : 263-270.
53. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011 ; 50 : 193-211.
54. Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60: 2386-2396.
55. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997 ; 100 : 1538-1546.
56. Mukhopadhyay P, Pan H, Rajesh M, Batkai S, Patel V, Harvey-White J, et al. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol 2010 ; 160 : 657-668.
57. Silva GB, Atchison DK, Juncos LI, Garcia NH. Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors. Am J Physiol Renal Physiol 2013 ; 304 : F376-81.
58. Diffley M, Armenian P, Gerona R, Reinhartz O, Avasarala K. Catecholaminergic polymorphic ventricular tachycardia found in an adolescent after a methylenedioxymethamphetamine and marijuanainduced cardiac arrest. Crit Care Med 2012 ; 40 : 2223-2226.
59. Loeffler G, Penn A, Ledden B. "B ath salt" - induced agitated paranoia: a case series. J Stud Alcohol Drugs 2012 ; 73 : 706.
60. Shanks KG, Dahn T, Terrell AR. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 2012 ; 36 : 145-152.
61. Federal Register. Temporary scheduling of XLR-11. Published 2013 Apr 12.